Skip to main content
. Author manuscript; available in PMC: 2017 Sep 1.
Published in final edited form as: Transl Res. 2016 Mar 31;175:103–115.e4. doi: 10.1016/j.trsl.2016.03.017

Figure 1.

Figure 1

A) Cumulative incidence of NRM day 100 after RIC HCT in patients with first dose F-ara-A Clpred <8.50L/hr (cumulative incidence [95%CI] 25% [6-43%]) compared to patients with F-ara-A Clpred ≥ 8.50 L/hr (cumulative incidence [95%CI]: 6% [3-10%]).

B) Cumulative incidence of NRM day 100 after RIC HCT in patients with first dose F-ara-A AUCpred ≥ 6.00 μg*hr/mL (cumulative incidence [95%CI] 22% [8-37%]) compared to patients with F-ara-A AUCpred <6.00 μg*hr/mL (cumulative incidence [95%CI] 6% [3-9%]).

C) Cumulative incidence of acute GVHD (grades II-IV) at month 6 after RIC HCT in patients with first dose F-ara-A Clpred <13.0 L/hr (cumulative incidence [95%CI] 45% [38-52%]) compared to patients with F-ara-A Clpred ≥13.0 L/hr (cumulative incidence [95%CI] 23% [7-39%]).